Devices and Methods for Analyte Assays with Built-In Result Reporting Using Recognizable Symbols

ABSTRACT

The present invention provides devices, methods and kits for detecting the presence of an analyte in a liquid sample. The invention provides devices having a positive control area covered with an opaque, movable material, such as an ink, dye, or other material, that is moved on the device by the flow of liquid sample, thereby exposing the positive control area underneath. Using the interaction of colored signals from the positive control area and the analyte binding area, a recognizable symbol is revealed on the device that correlates with the test results, and appears as the test is conducted.

CROSS REFERENCE TO RELATED APPLICATIONS

This application is a continuation application of U.S. application Ser.No. 11/016,371 filed Dec. 17, 2004, now issued as U.S. Pat. No.7,297,502. The disclosure of the prior application is considered part ofand is incorporated by reference in the disclosure of this application.

BACKGROUND OF THE INVENTION

1. Field of the Invention

The present invention is directed to devices for the detection of ananalyte and the presentation of test results in as recognizable symbols.

2. Background Information

The following Background of the Invention is intended to aid the readerin understanding the invention and is not admitted to be prior art.

The inclusion of positive and negative control tests in the performanceof an assay is an important component for verifying the validity of theresults of any assay. A variety of methods have been used to introduceand include control testing in various assay format. For example,control tests have been included in immunological test formats byutilizing a control zone where analyte is bound to a control line in theassay. Thus, a colored line appears when a labeled control reagent isbound at the control line. These and other types of control tests areeffective for verifying that the assay device is functioning correctly,but they also result in added expense and inefficiency in manufacturingthe devices and performing the assays, particularly when the specificbinding molecules used in the control test are produced as a result ofelaborate procedures. Additionally, these types of controls can beconfusing for the untrained general consumer and lead to improper testinterpretation. There is therefore a need for better and more efficientdevices and methods for performing sample testing.

SUMMARY OF THE INVENTION

The present invention provides devices, methods and kits for detectingthe presence of an analyte in a liquid sample and indicating to the userthe presence or absence of the analyte with recognizable symbols. In oneembodiment the present invention provides test strips having a sampleapplication zone, a reagent zone and a detection zone. The detectionzone contains a positive control area, a negative control area, and ananalyte binding area. The positive control area is delineated by acolored symbol, in this embodiment a minus sign. The analyte bindingarea is adjacent to and interacts with the positive control area. Theanalyte binding area contains binding reagents to capture a labeledanalyte. In one embodiment, the positive control area or a portion ofthe detection zone (or the entire detection zone) is covered with anopaque, movable material, for example a dye or ink. At the beginning ofthe assay, the positive control area is obscured by the opaque, movablematerial until liquid sample reaches the detection zone. When the liquidsample flows through the detection zone, the opaque, movable material iswashed away and the positive control area becomes visible. If no analyteis present in the sample, the revealed positive control area shows theminus sign and the analyte binding area shows no color, indicating anegative result. But if analyte is present in the sample, the labeledanalyte binds to the analyte binding area. The positive control area andthe analyte binding area interact with each other and produce a plussign visible to the user. The invention also provides methods of usingthe devices, and kits containing the devices.

In a first aspect the present invention provides a device for performingan assay to detect the presence or absence of an analyte in a sample.The device has a matrix that supports the flow of a liquid sample, anapplication zone on the matrix for receiving a liquid sample, and adetection zone on the matrix with a symbol affixed thereto. Thedetection zone (and the symbol) is at least partially obscured by anopaque, movable material. One or more reagent zones are present on thematrix, containing reagents for conducting the assay. A wide variety ofanalytes can be tested for using the present invention, for examplehuman chorionic gonadotropin, leutenizing hormone, follicle stimulatinghormone, specific and non-specific proteins, blood or blood components,antibodies, drugs and drugs of abuse, urea, nitrite, and glutaraldehyde.

In one embodiment the detection zone contains an analyte binding areaand a positive control area. The matrix can be a bibulous material, andthe opaque, movable material can be a water soluble ink. For example,the matrix can be a nitrocellulose assay strip and the positive controlarea is in the shape of a minus sign situated longitudinally on theassay strip. In a related embodiment, the analyte binding area iscomprised of two areas situated on either side of the positive controlarea having a specific binding molecule that binds to the analyte, or toa molecule bound to the analyte. The positive control area and analytebinding area interact to form a recognizable symbol when analyte ispresent in the sample. In various embodiments the recognizable symbolcan be a plus sign, a minus sign, an “X.” or another symbol known in theart or in general parlance as conveying a particular meaning. In oneembodiment the opaque, movable material is a water soluble ink thatcovers the positive control area. The specific binding molecule can bean antibody or antibody fragment. In one embodiment the analyte is humanchorionic gonadotropin.

In related embodiments the positive control area is delineated by one ormore colored zones on the bibulous material and does not comprise amember of a specific binding pair. The analyte can be bound with a labelproviding a detectable signal, and the label can be a colored particleor a dextran bead. The analyte binding area can be a bar situatedlatitudinally along the axis of the strip, and can also have a specificbinding molecule for the analyte, or for a molecule bound to theanalyte.

In another embodiment the label and the positive control area are of thesame color. The device can have a sample pad situated at a first end ofthe device, a detection zone situated near the middle of the test strip,and a label pad situated between the sample pad and detection zone.

Another aspect of the present invention provides for methods ofdetermining the presence or absence of an analyte in a liquid sampleusing the device of the present invention. The methods involve placingthe liquid sample onto the application zone of a device of the inventiondescribed herein, allowing the liquid sample to flow through the matrixand thereby pass through the one or more reagent zones so that reagentsfor conducting the assay react with the liquid sample to form adetectable reaction product when analyte is present in the liquidsample, allowing the liquid sample to flow through the detection zone atleast partially obscured by an opaque, movable material, thereby washingaway the opaque, movable material to expose a positive control area sothat analyte contained in the sample is restrained on the analytebinding area as sample flows through the detection zone, and observingthe detection zone of the device to determine the presence or absence ofanalyte in the liquid sample.

In one embodiment, the liquid sample washes away the soluble ink asliquid sample flows through the detection zone, thereby exposing thepositive control area. In a related embodiment the positive control areacan be two bars situated on either side of the analyte binding area, andthe positive control area and analyte binding area interact to form arecognizable symbol.

In another aspect, the present invention provides kits containing adevice of the invention as described herein, and instructions for use ofthe device. In one kit, the instructions are for use of the device fordetermining the presence or absence of an analyte in a liquid sample.

The present invention includes a variety of other useful aspects, whichare detailed herein. These aspects of the invention can be achieved byusing the articles of manufacture and compositions of matter describedherein. With reference to the present disclosure, it will be furtherrecognized that various aspects of the present invention can be combinedto make desirable embodiments of the invention. In addition, a varietyof other aspects and embodiments of the present invention are describedherein.

The summary of the invention described above is not limiting and otherfeatures and advantages of the invention will be apparent from thefollowing detailed description, as well as from the claims.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 provides a top view of one embodiment of the device, having atest strip 10, and including an application zone 15, a reagent zone 17,a detection zone 12, a negative control area 19, a positive control area11, and an analyte detection area 13. The direction of sample flow isillustrated by an arrow.

FIG. 2 illustrates one embodiment of the device prior to use, when theentire detection zone is covered by the opaque, movable material 20. Thepositive control area, is located below the opaque, movable material,which is shown covering the detection zone.

FIG. 3 illustrates another embodiment of the device prior to use, whereonly the positive control area is covered by the opaque, movablematerial. The positive control area is located below the opaque, movablematerial 20, and is shown as a shadow.

FIG. 4 illustrates the embodiment of FIG. 3 after sample has flowed fromthe sample application zone to the opposite end of the test strip, whenno analyte is present in the applied sample. Note that in thisembodiment, the positive control area appears as a minus sign.

FIG. 5 illustrates the appearance of the device of FIG. 1 after samplehas flowed from the application zone to the opposite end of the teststrip, when analyte is present in the applied sample. Note that in thisembodiment, the positive control area and the analyte detection zoneinteract to appear as a plus sign.

FIG. 6 illustrates one embodiment, in which a plus sign is formed by theinteraction of the analyte detection area 13 with the positive controlarea 11, which overlaps the analyte detection area.

FIG. 7 illustrates a second embodiment, in which a plus sign is formedby the positive control area 11 overlapping the analyte detection zone13.

FIG. 8 illustrates another embodiment, in which the positive controlarea is composed of multiple, aligned bars that are perpendicular to andabut the analyte detection area, and thus appear as a plus sign.

FIG. 9 illustrates an alternative embodiment in which the analytedetection area 13 is composed of multiple, aligned bars that areperpendicular to and abut the positive control area 11, and thus appearas a plus sign.

FIG. 10 illustrates another embodiment, in which the analyte detectionarea 13 and positive control area 11 interact to form an “X.” In thissituation, the analyte detection and positive control areas are placedat an angle to the direction of sample flow.

FIG. 11 illustrates a further embodiment, in which the analyte detectionarea 13 and positive control area 11 interact to form a “Y.”

DETAILED DESCRIPTION OF THE INVENTION

In the following detailed description, reference is made to theaccompanying drawings that form a part hereof, and in which is shown byway of illustration specific embodiments in which the invention may bepracticed. It is understood that other embodiments may be utilized andstructural changes may be made without departing from the scope of thepresent invention.

Test Devices

The devices of the invention can utilize test strips to detect thepresence of an analyte in a liquid sample. The devices use theinteraction of colored signals from the positive control area and theanalyte binding area to form a recognizable symbol that provides thetest result. FIGS. 1-3 illustrate one embodiment of the present deviceprior to use, a test strip having a matrix that supports the flow of aliquid sample. The device includes an application zone 15 where liquidsample is applied to the device, a reagent zone 17, and a detection zone12. The reagent zone 17 contains reagents for conducting the assay, andmore than one reagent zone can be present on the device depending on therequirements of the particular assay being conducted. The detection zoneincludes a positive control area 11, an analyte binding area 13 (or testarea) and a negative control area 19. The direction of sample flow isindicated in the Figures by an arrow. The sample application zone cancontain a buffer for solubilizing the sample, or can be simply alocation on the matrix for the application of sample, but it also cancontain other reagents for conducting the assay. The sample applicationzone can therefore also be a reagent zone. Sample is advantageouslyapplied in a liquid form to begin the assay, but can also be dried onthe test strip and the assay begun by applying water, buffer, or otherreagents to solubilize the sample and begin the assay. The sample itselfcan be a liquid sample, or a solid sample that has been liquefied orotherwise prepared in a liquid form. The reagents contained in thereagent zone can be movably present in the reagent zone. Some reagentscan be attached to a label and bind to analytes of interest present inthe sample., thereby providing a labeled analyte. The sample applicationzone and/or reagent zone can also contain buffers for solubilizing thesample or adjusting the pH, as may be required in the specific assay.The test strip is generally a bibulous material providing a matrix tosupport the flow of liquid. “Matrix” refers to a material that supportsthe flow and transport of fluid through the device. In one embodimentthe matrix is a bibulous material. The flow of fluid through the devicecan be by force of capillary action. In different embodiments the matrixcan be a strip of a single material or may be assembled from more thanone bibulous material that are in fluid communication with each other.“Bibulous” materials are those that readily absorb liquid and throughwhich liquid is transported by capillary action. Examples of bibulousmaterials include nitrocellulose, filter paper, glass fibers, polyester,and other suitable materials.

Symbols

Recognizable symbols are created by the interaction of the positivecontrol and analyte binding areas on the device. The positive controlarea can be delineated by choosing a portion of a symbol that willinteract with the analyte binding area, and affixing the shape to formthe positive control area. The symbol (or portion of a symbol) can beaffixed to form the positive control area by methods known in the art,for example by printing or painting the symbol onto the matrix, or byattaching colored particles to a protein and attaching the protein to,within, or underneath the matrix.

In various embodiments the “recognizable symbol” can be a plus sign, aminus sign, a dash, a bar, an “X,” or another symbol known in the art orin general as conveying a particular meaning that can be associated withthe assay result. Any meaningful symbol can be selected, such as aletter from the Roman alphabet, a number, a mathematical operator, ascientific symbol, or a letter from another language or alphabet system,for example a letter from the Chinese, Japanese, or Arabic alphabets.For example, a minus sign is advantageously used to indicate a negativeresult, because it is a meaningful and easily recognized symbol, and canalso be conveniently configured to interact with an analyte binding areato form a plus sign. Other symbols, such an “X,” “O,” null sign, “Y,”“N,” “Z,” or an arrow, can also be selected. These symbols can be easilyread and understood by an untrained user. When the detectable label andthe demarcation of the positive control area are selected to be the samecolor, the recognizable symbol is formed by the interaction of thepositive control area and the analyte binding area when a positiveresult is obtained. When the symbol is a minus sign, it can have eithersquare or rounded edges.

Positive Control Area

The detection zone of the device contains the positive control area,negative control area, and the analyte binding area. The negativecontrol area is that space located in the detection zone that is not apart of either the positive control area or analyte binding area. If adetectable signal from the detectable label is provided in this area,the assay is invalid due to a failed negative control. In someembodiments the detection zone is a rectangle or square on a bibulousmatrix that encompasses the length of the positive control area oranalyte binding areas, measuring longitudinally along a test strip, andis further encompassed by lines drawn perpendicular to the sides of thetest strip.

The positive control area can be delineated by one or more colored areason the device and in some embodiments does not contain a member of aspecific binding pair. In the embodiment shown in FIG. 4, the positivecontrol area takes the form of a colored symbol affixed to the detectionzone, in this case a minus sign situated longitudinally on the assaystrip. By “longitudinally” is meant parallel to the direction of sampleflow, which generally will be along the length of the matrix. Thepositive control area may be made by affixing a dye or ink to thematrix, or to a structure underneath the matrix. For example, in thoseembodiments where a backing is used, the dye, ink, or other materialdemarcating the positive control area can be affixed on the top orbottom of the backing. The positive control area can also be placed on astructure underneath the test strip, such as situated between the matrixand the housing of the device. The structure can be a piece of plasticor other material with a mark on it. Alternatively, the positive controlarea can be marked on the housing of the device. Examples of suitabledyes or inks to demarcate the positive control area include, but are notlimited to, 3132 fast red 2R, 4230 Malachite blue lake, blue coloredlatex beads conjugated with BSA, and gold labeled IgG. Of course, manyother dyes, inks, or colored materials can also be used and those arenot excluded by these examples.

Opaque, Movable Material

In certain embodiments, the opaque, movable material covers only thepositive control area (FIG. 3), but in other embodiments it can coverthe entire detection zone (FIG. 2), or some portion thereof, or thepositive control area and a portion of the detection zone, or a portionof the matrix outside of the detection zone. An “opaque, movablematerial” is a material that does not transmit an amount of lightsufficient to easily view a symbol contained underneath under ordinaryroom lighting, but which is movable by force of an aqueous solutionflowing through or over the matrix. Thus, the symbol containedunderneath the opaque, movable material is obscured from view. In someembodiments the symbol is completely obscured, while in others aquantity of light may pass through the material sufficient to discern afaint symbol underneath, but without detrimental effect on interpretingor using the device. Thus, in these embodiments the symbol is not easilyviewed, but nevertheless can be discernable.

In the Figures, the positive control area is shown as a shadow. However,in an actual device, the positive control area is obscured from view bythe opaque movable material. In one embodiment the opaque, movablematerial is soluble in an aqueous solution. By “soluble” is meant thatan aqueous liquid sample flowing through the detection zone will exposethe symbol present underneath the opaque, movable (soluble) material bywashing or moving it off of the symbol, such that the symbol is clearlyvisible to the unaided eye under ordinary room lighting.

When a soluble dye is used as the opaque, movable material, generallyany convenient soluble dye can be used, as long as it is sufficientlyopaque and is soluble in an aqueous solution. A variety of coloredmobilizable dyes can be used. Ponceau 4R and Green coloring matter(Shanghai Dye Institute, Shanghai, China), Rose Red (lot 020811 fromShanghai Marine Painting Materials Company, Shanghai, China), watercolorpigments, and commonly available food colorings all may be used to goodeffect. In one embodiment the opaque, movable material is a whitecolored dye. A white titanium oxide (TiO₂) food additive can also beused. Thus, when the dye covers and obscures the positive control area,no symbol at all is apparent to the user and the detection zone blendsin with the other portions of the matrix. Of course, any color ofopaque, movable material can be used, depending on considerationsimportant to the user. The opaque, movable material can be sprayed ontothe positive control area, or layered or painted, or applied using anyconvenient technique. In other embodiments the opaque, movable materialcan be a particulate substance, such as latex beads or other particularmaterial, as long as the material will be moved off of the positivecontrol area by the flow of fluid.

In one embodiment, the opaque, movable material is selected to be adifferent color than the positive control area so that when the materialis moved off of the positive control area, a symbol of different colorthan was initially present is apparent and is available to interact withcolor that may be produced in the analyte binding area.

Analyte Binding Area

The analyte binding area is positioned on the matrix so that itinteracts with the positive control area, so that together the two areasprovide an apparent detectable symbol when the analyte of interest ispresent in the liquid sample. Labeled reagents present in a reagent zonecan bind to the analyte of interest, thereby labeling the analyte ofinterest with a detectable label as it flows through the matrix. Theanalyte binding area also contains reagents that bind to a moietyassociated with the analyte. That moiety can be an immunological epitopeon the analyte itself, or a reagent bound to the analyte (e.g., from thereagent zone). In various embodiments the reagent bound to the analytecan be an antibody, a fraction or portion of an antibody, an antibody(or fragment thereof) derived from a species different from the antibodyaffixed to the analyte binding area, or another member of a specificbinding pair, for example, avidin, streptavidin, or biotin, which itselfcan be bound to a moiety bound to the analyte.

The analyte binding area can be a bar situated latitudinally along theaxis of the strip, and contain a specific binding molecule for theanalyte, or for a molecule bound to the analyte. The analyte bindingarea can also be two areas on either side of the positive control zoneso that when analyte is present in the sample, it is labeled during theassay and is retained at the analyte binding area. The interactionbetween the color at the analyte binding area and the positive controlarea provide the recognizable symbol. In some instances the label is acolored particle, which may be a dextran bead, gold sol, or otherlabeling particle.

Reagent Zone

The label that binds the analyte of interest serves to provide thevisually detectable signal in the analyte binding area, which willinteract with the positive control area to form the recognizable symbolwhen analyte is present in the sample. Specific binding molecules forthe analyte carrying a label can be present in the reagent zone. Whenthe specific binding molecules capture the analyte, and when the labeledanalyte is bound within the analyte binding area, the area becomesvisible due to the accumulation of the label in the area. A “specificbinding molecule” for the analyte refers to a binding molecule thatbinds to the analyte and does not substantially bind to any othermolecule present in the sample. The specific binding molecule for theanalyte can also bind to a molecule that correlates with or indicatesthe presence of analyte in the sample. By substantial binding is meantthat binding occurs to an extent that will affect the result of theassay. In some embodiments the specific binding molecule can be anantibody or an antibody fragment (e.g., the Fab region of an antibody),an antigen, a receptor or fragment of a receptor that binds a ligand, ora member of a biotin-streptavidin pair or other type of binding pair.

A label can thus be provided in the reagent zone, and as the sampleflows through the reagent zone the analyte is bound with a label thatprovides a detectable signal. A “label pad” is an area of the matrixwhere there is present a label for the analyte suspected of beingpresent in the sample. Therefore, a reagent zone can be a label pad. The“label” can be any suitable label that provides a detectable signal. Forexample, the label can be a sol particle, a fluorescent molecule, achemiluminescent molecule, a metal or alloy (e.g. colloidal gold), or asac, in particular a liposome containing a visible dye. Also useful arehydrophobic sols, which hydrophobic organic dyes or pigments areinsoluble in water or soluble only to a very limited extent. The labelcan also be polymer particles, such as colored polystyrene particles(e.g., spherically shaped). Other useful particulate labels includeferritin, phycoerythrins or other phycobili-proteins, precipitated orinsoluble metals or alloys, fungal, algal, or bacterial pigments orderivatives such as bacterial chlorophylls, or other plant materials. Incertain embodiments, the label is a colored particle, such as a dextranbead. In other embodiments, the label and the dye used for the positivecontrol are selected to have similar colors, to enhance the interactionof the two signals in producing a single apparent symbol on or in thematrix.

In other embodiments, the label can be a labeled antibody to theanalyte. For example, if the analyte of interest is human chorionicgonadotropin (hCG), the label that attaches to the hCG is gold-sollabeled anti-hCG antibody. When the sample reaches the reagent zone (orlabel pad), the hCG present in the sample is bound by the gold-anti-hCGantibody. The labeled antibody does not interfere with capture antibodypresent in the analyte binding area, which binds the labeled hCG. ThehCG-anti-hCG antibody-gold complex migrates downstream in the matrix.When the complex reaches the analyte binding area the capture antibody,another anti-hCG antibody, binds to another part of the hCG molecule toform a complex of gold-anti-hCG antibody-hCG-anti-hCG antibody. When thegold-anti-hCG antibody-hCG-anti-hCG antibody complex is bound to theanalyte binding area, the analyte binding area is colored by the goldlabel on the complex and therein becomes visible to the unaided eye.

“Antibody” refers to an immunoglobulin, whether natural or partially orwholly synthetically produced. The term also includes derivativesthereof which maintain specific binding ability. The term also coversany protein having a binding domain which is homologous or largelyhomologous to an immunoglobulin binding domain. These proteins may bederived from natural sources, or partly or wholly syntheticallyproduced. An antibody may be monoclonal or polyclonal. The antibody maybe a member of any immunoglobulin class, including any of the humanclasses: IgG, IgM, IgA, lgD, IgG, and IgE. An “antibody fragment” is anyderivative of an antibody which is less than full-length. The antibodyfragment can retain at least a significant portion of the full-lengthantibody's specific binding ability. Examples of antibody fragmentsinclude, but are not limited to, Fab, Fab′, F(ab′)₂, scFv, Fv, dsFvdiabody, and Fd fragments.

The antibody fragment may be produced by any means. For instance, theantibody fragment may be enzymatically or chemically produced byfragmentation of an intact antibody or it may be recombinantly producedfrom a gene encoding the partial antibody sequence. Alternatively, theantibody fragment may be wholly or partially synthetically produced. Theantibody fragment may optionally be a single chain antibody fragment.Alternatively, the fragment may comprise multiple chains which arelinked together, for instance, by disulfide linkages. The fragment mayalso optionally be a multimolecular complex. A functional antibodyfragment will typically comprise at least about 50 amino acids and moretypically will comprise at least about 200 amino acids.

Single-chain Fvs (scFvs) are recombinant antibody fragments consistingof only the variable light chain (V_(L)) and variable heavy chain(V_(H)) covalently connected to one another by a polypeptide linker.Either V_(L) or V_(H) may be the NH₂ -terminal domain. The polypeptidelinker may be of variable length and composition so long as the twovariable domains are bridged without serious steric interference.Typically, the linkers are comprised primarily of stretches of glycineand serine residues with some glutamic acid or lysine residuesinterspersed for solubility. “Diabodies” are dimeric scFvs. Thecomponents of diabodies typically have shorter peptide linkers than mostscFvs and they show a preference for associating as dimers.

An “Fv” fragment consists of one V_(H) and one V_(L) domain heldtogether by noncovalent interactions. The term “dsFv” is used herein torefer to an Fv with an engineered intermolecular disulfide bond tostabilize the V_(H)-V_(L)pair. A “F(ab′)₂” fragment is an antibodyfragment essentially equivalent to that obtained from immunoglobulins(typically IgG) by digestion with an enzyme pepsin at pH 4.0-4.5. Thefragment may be recombinantly produced. A “Fab” fragment is an antibodyfragment essentially equivalent to that obtained by reduction of thedisulfide bridge or bridges joining the two heavy chain pieces in theF(ab′)₂ fragment. The Fab′ fragment may be recombinantly produced. A“Fab” fragment is an antibody fragment essentially equivalent to thatobtained by digestion of immunoglobulins (typically IgG) with the enzymepapain. The Fab fragment may be recombinantly produced. The heavy chainsegment of the Fab fragment is the Fd piece.

The recognizable symbol is formed by the interaction of the positivecontrol area and the analyte binding area. This can be accomplished inseveral ways, illustrated in FIGS. 6-11. These are intended asnon-limiting examples. Symbols of other shapes, such as circles andtriangles, are also contemplated.

Prior to use of the device the analyte binding area is not visible tothe user. In certain embodiments, the test result will be a plus sign ora minus sign, depending upon the presence or absence of analyte in thesample (FIGS. 4 and 5). FIG. 4 depicts the test results when no analyteis present in the sample. The positive control area has become visible,as a minus sign, since the opaque, movable material has been washed fromthe detection zone by the movement of liquid sample and migrated to theend of the test strip. FIG. 5 illustrates the test results when analyteis present in the sample; the analyte reacts with the labeled reagentand is captured by the analyte binding area. The analyte binding area issituated latitudinally on the assay strip. By “latitudinal” is meantperpendicular to the direction of fluid flow through the device, whichis usually also perpendicular to the length of the test strip. Thepositive control area and the analyte binding area are situated on thetest strip so that they interact with each other and their signals takentogether produce a recognizable symbol. In the present example, thesymbol is a plus sign. In alternative embodiments, the analyte bindingarea can be arranged with the positive control area to form otherrecognizable signs.

FIG. 6 illustrates one embodiment, in which a plus sign is formed by theanalyte detection zone overlapping the positive control area. In thisexample, the positive control area is laid down longitudinally on thetest strip, followed by application of the analyte binding area on topof the positive control area. In different embodiments these areas mayor may not overlap. The ink or dye used for the positive control and theanalyte label can be selected to be of similar colors, so that thepositive control area and the analyte binding area will form a singlesymbol when they interact. In this case, the positive test symbol is aplus sign. A negative test result produces a minus sign.

FIG. 7 illustrates another embodiment, in which a plus sign is formed bythe positive control area and the analyte detection zone, which may ormay not overlap. This is similar to the example shown in FIG. 6, exceptthat the analyte binding area is applied to the test strip before thepositive control area. Similar to the previous example, a positive testresult symbol, with the present arrangement of zones, is a plus sign. Anegative test result produces a minus sign.

In another embodiment the positive control can be place laterally on thetest strip, and the analyte binding area placed longitudinally. In thisorientation, the positive test result symbol would still be a plus signand a negative test result symbol would be a minus sign.

FIGS. 8 and 9 illustrate alternative methods of making plus signs withthe positive control and analyte binding area signals. In the embodimentdepicted in FIG. 8, the positive control area is composed of multiple,aligned bars (instead of a single bar) that are perpendicular to andabut the analyte detection zone, and thus form a plus sign. In analternative embodiment, the analyte binding area is composed ofmultiple, aligned bars that are perpendicular to and abut the positivecontrol area, which together form a plus sign.

FIG. 10 illustrates another embodiment of the present invention, inwhich the test and positive control areas interact to form an “X.” Inthis situation, the test and positive control areas are placed at anangle to the direction of sample flow. FIG. 11 illustrates a furtherembodiment, in which the test and positive control areas interact to fora “Y.”

Type of Analytes

The analyte being assayed for presence or absence using the presentinvention can be any analyte. Examples of analytes that can be readilytested for using the present invention include (but are not limited to)human chorionic gonadotropin (hCG), leutenizing hormone, folliclestimulating hormone (FSH), hepatitis C virus (HCV), hepatitis B virus,hepatitis B surface antigen, HIV, and any drug of abuse. Also, analytecan be detected in any liquid or liquefied sample such as, for example,urine, saliva, oral fluid, blood, plasma, or serum. Additional examplesof analytes to be tested for include but are not limited to creatinine,bilirubin, nitrite, protein (nonspecific), blood, leukocytes, sugar,heavy metals or toxins, bacterial components (e.g. proteins or sugarsspecific to a particular type of bacteria, such as E. Coli 0157:H7, S.aureus, Salmonella, C. perfringens, Campylobacter, L. monocylogenes, Vparahaemolyticus, or B. cereus). Any other analyte that can be adaptedto a lateral flow test format may also be incorporated into the presentdevice.

Types of Samples

Any sample type can be tested with the device of the present inventionincluding liquids of biological origin (e.g., body fluids and clinicalsamples). Liquid samples may be derived from solid or semi-solidsamples, including feces, biological tissue, and food samples. Suchsolid or semi-solid samples can be converted into a liquid sample by anysuitable method, for example by mixing, chopping, macerating,incubating, dissolving or enzymatically digesting solid samples in asuitable liquid (e.g., water, phosphate-buffered saline, or otherbuffers). “Biological samples” include samples derived from livinganimals, plants, and food, including for example urine, saliva, bloodand blood components, cerebrospinal fluid, vaginal swabs, semen, feces,sweat, exudates, tissue, organs, tumors, tissue and organ culture, cellcultures and conditioned media therefrom, whether from humans oranimals. A preferred biological sample is urine. Food samples includesamples from processed food components or final products, meat, cheese,wine, milk and drinking water. Plant samples include those derived fromany plant, plant tissue, plant cell cultures and conditioned mediatherefrom. “Environmental samples” are those derived from theenvironment (e.g., a water sample from a lake or other body of water,effluent samples, soil samples, ground water, ocean water, and runoffwater. Sewage and related wastes can also be included as environmentalsamples.

Methods of Use

The present invention also provides methods of using the devices of theinvention to detect the presence or absence of an analyte in a liquidsample. The methods can include the steps of placing a liquid sampleonto the application zone of a device of the present invention, andallowing the sample to begin flowing through the test strip. The liquidsample can be placed on the sample application zone by any convenientmeans, for example by using a dropper.

With reference to FIG. 1, after application of liquid or liquefiedsample to the sample application zone 15, the sample begins flow throughthe matrix and down the test strip. The sample enters a reagent zone 17where reagents for conducting the assay and/or for labeling the analytereact with the sample. The analyte present in the sample is thereforelabeled with a detectable label, in this case an antibody for theanalyte carrying a gold sol particle. Of course the label can be anyconvenient label, for example a gold sol, or an enzyme, or a latexparticle. At the beginning of the assay, the detection zone 12 is atleast partially obscured by an opaque, movable material, in this casethe opaque, movable material covers the positive control area 11. As thesample flows through the detection zone, the movement of the liquidsample washes away the opaque, movable material to expose the positivecontrol area underneath. Also, analyte contained in the fluid sample(and which is now labeled with a detectable label) is restrained on theanalyte binding area 13, which contains a member of a specific bindingpair for a moiety associated with the analyte, in this case an antibodydirected to an epitope directly on the analyte.

The positive control area 11 and the detectable label are selected tohave the same color, so that when labeled analyte binds to the analytebinding area 13, the interaction of the positive control area and theanalyte control area results in the appearance of a recognizable symbolin the detection zone, in this case a “+” sign.

In cases where no analyte is present in the sample, the primary symbol(the minus sign of the positive control area 11 is apparent in thedetection zone, resulting in a minus sign becoming visible after theassay is complete and indicating a negative result for the assay.

Test Kits

The present invention also provides kits containing one or more devicesof the present invention, and instructions for use in carrying out anassay. The test kits can be packaged in a variety of formats, dependingupon the customer's needs.

In one embodiment, the kits contain devices that are “midstream”fertility test devices, and instructions for using the devices to detecthGH in a urine sample, which indicates a state of pregnancy. Theinstructions explain how to perform the test and interpret the testresults. For example, a woman using the test urinates on the wick, whichtransfers some of her urine to the test strip. After a few minutes, theopaque, movable material is washed away. If the test is negative (thewoman is not pregnant), a minus sign is uncovered when the opaque,movable material washes away. If the test is positive (the woman ispregnant), a plus sign is uncovered when the opaque, movable materialwashed away, and hCG bound with a detectable label is restrained in theanalyte binding area, thereby providing the recognizable symbol.

In another embodiment the kits contain 6, 7, 8, 9, 10, 11, or 12, ormore than 3, or more than 4, or more than 5 ovulation test devices and1, 2, or 3, or more than 1 fertility test devices and instructions.These devices are configured to detect the surge in leutenizing hormone(LH) which precedes ovulation. In this embodiment the instructionsrelate to use of the test devices in pinpointing the LH surge. Inanother embodiment the instructions explain female hormonal andovulation cycles, and how to identify the time of ovulation.

In another embodiment, test strips of the present invention areconfigured for pregnancy testing in a professional laboratory. The kitsinclude a number of test devices as described above, and optionallyinclude an instruction insert. The kit can contain more than 15 or morethan 20 test strips. This type of kit is convenient for use in point ofcare facilities since it provides a larger number of devices.

EXAMPLE 1 Construction and Testing of Midstream hCG Test Devices

This example describes the construction and use of devices for testingthe presence or absence of hCG. This Example uses a green food additiveas the opaque, colored material to cover the positive control area. TheExample shows that the devices prepared are able to correctly determinethe presence of the analyte of interest (hCG) and to provide distinctrecognizable symbols for positive and negative test results.

hCG test strips were constructed according to methods known in the art,except where otherwise noted. First, gold sol-labeled goat anti-mouseIgG (1.3 mg/ml, as procedural control line) was applied to anitrocellulose membrane using a microsyringe controlled by amicroprocessor. Mouse anti-αhCG IgG (4.0 mg/ml) was also applied tobecome the test line, manifested as the analyte binding areas and toform the vertical line of the positive plus sign when hCG is present inthe sample. The deposition intensity used was 1.1 μl/cm. Immediatelyafter application, the membrane was dried at 45° C. (2 hours) toimmobilize the antibody reagent.

A solution was made by combining apple green food color (1% finalconcentration; Shanghai Dyestuffs Research Institute, Shanghai, China,lot 99031923) and gold labeled goat anti-mouse IgG (final OD₅₂₀=121) inNa₂HPO₄ buffer (50 mM final concentration). This solution was applied tothe positive control area on the nitrocellulose membrane, to become theprimary recognizable symbol (a “minus” sign) in the detection zone. Thissymbol present by itself after an assay indicates a negative testresult. The solution was applied at a deposition intensity of 0.8 μl/cm.This was done so that a 10 mm line of this solution was striped ontoeach test strip (to be cut out) from 22 mm to 32 mm from the upstreamedge of the test strip. Immediately after application, the membrane wasdried overnight at 55° C.

After drying the reagent zone and sample application zone were laminatedto the membrane. An absorbent paper was also included to facilitate themovement of fluid through the device. The larger, laminated card was cutinto individual test strips of about 60 mm×7.2 mm. The individual teststrips were then assembled into midstream test devices, and wicks werealso included in the devices. The midstream casing has two windows, onefor the test results and one for a procedural control. Prior to use thetest window contains a green minus sign and the control window is empty.

1 ml of three urine samples having 0 mIU/ml hCG, 25 mIU/ml hCG, and 100mIU/ml hCG was applied to three devices in each category, performed intriplicate for a total of 27 devices. A set of three devices in eachcategory would be observed at 3 min, 7 min, and 10 min. As the liquidsample flowed through the matrix, the green dye was washed away from thetest window, revealing the red minus sign present underneath as thepositive control area. In each of the samples containing 0 mIU/ml ofhCG, the red minus sign was present by itself, indicating a negativeresult in all three time periods.

In those samples containing 25 mIU/ml or 100 mIU/ml of hCG, the hCGpresent was labeled with an antibody, which was labeled with gold sol,as it flowed through the matrix of the device. When the labeled hCGreached the analyte binding area, it was bound to the area, therebyconcentrating the labeled hCG in the analyte binding area, and causingthe analyte binding area to appear red in color.

After the assay was complete, the detection zone of the device wasobserved. In the samples containing 25 mIU/ml of hCG, all of the deviceshad a red positive control area and a red analyte binding area within 10min of start of the assay. The positive control area and analyte bindingarea interacted to appear as a plus sign in the detection zone.

In the devices for the 100 mIU/ml of hCG category, all three devices ineach time period showed a plus sign in the detection zone at 3 minutesfrom start of the assay, thus indicating a positive result for thepresence of hCG.

The devices and methods of the invention are useful in a variety offormats. For example, they are useful in a professional laboratoryformat, such as a point of care facility performing pregnancy tests, orfor pinpointing the time of ovulation by identifying the time of thesurge of leutenizing hormone. The devices will also be useful in a hometesting format for the same purposes. The devices are also useful incontexts apart from fertility testing and can be used to detect thepresence of any analyte in any liquid or liquefied sample. The kitsdescribed herein are prepared to meet the specific needs of theapplication of the devices.

The invention illustratively described herein may be practiced in theabsence of any element or elements, limitation or limitations that arenot specifically disclosed herein. The terms and expressions which havebeen employed are used as terms of description and not of limitation,and there is no intention that in the use of such terms and expressionsof excluding any equivalents of the features shown and described orportions thereof, but it is recognized that various modifications arepossible within the scope of the invention claimed. Thus, it should beunderstood that although the present invention has been specificallydisclosed by various embodiments and optional features, modification andvariation of the concepts herein disclosed may be resorted to by thoseskilled in the art, and that such modifications and variations areconsidered to be within the scope of this invention as defined by theappended claims.

The contents of the articles, patents, and patent applications, and allother documents and electronically available information mentioned orcited herein, are hereby incorporated by reference in their entirety tothe same extent as if each individual publication was specifically andindividually indicated to be incorporated by reference. Applicantsreserve the right to physically incorporate into this application anyand all materials and information from any such articles, patents,patent applications, or other documents.

1. A device for performing an assay to detect the presence or absence ofan analyte in a sample comprising: a matrix that supports the flow of aliquid sample; an application zone on the matrix for receiving theliquid sample; one or more reagent zones on the matrix comprisingreagents for conducting the assay; a detection zone on the matrix, thedetection zone comprising an analyte binding area and a positive controlarea demarcated on the matrix; wherein the analyte binding area and thepositive control area interact to form recognizable symbols indicativeof the presence or absence of analyte in the sample, and wherein atleast a portion of detection zone is covered by an opaque, water-solubledye.
 2. The device of claim 1 wherein the opaque, movable materialcovers only the positive control area.
 3. The device of claim 1 whereinthe analyte is selected from the group consisting of leutenizing hormone(LH), human chorionic gonadotropin (hCG), follicle stimulating hormone(FSH), hepatitis B surface antigen, human immunodeficiency virus (HIV),a bacteria-specific protein, creatinine, bilirubin, heavy metals,leukocytes, toxins, and a drug of abuse.
 4. The device of claim 1wherein the analyte is leutenizing hormone.
 5. The device of claim 1wherein the analyte is human chorionic gonadotropin.
 6. The device ofclaim 1 wherein the positive control area comprises two areas situatedat either side of the analyte binding area.
 7. The device of claim 1wherein the positive control area is in the form of a symbol, andwherein further the symbol comprises a color.
 8. The device of claim 7,wherein the opaque, water-soluble dye comprises a color that isdifferent from the color of the symbol of the positive control area. 9.A device for performing an assay to detect the presence or absence of ananalyte in a sample comprising: a matrix that supports the flow of aliquid sample; an application zone on the matrix for receiving theliquid sample; one or more reagent zones on the matrix comprisingreagents for conducting the assay; a detection zone on the matrix, thedetection zone comprising an analyte binding area and a positive controlarea demarcated on the matrix; wherein the analyte binding area and thepositive control area interact to form recognizable symbols indicativeof the presence or absence of analyte in the sample, and wherein atleast a portion of detection zone is covered by an opaque, movablematerial, wherein the opaque, movable material comprises beads.
 10. Thedevice of claim 9 wherein the beads cover only the positive controlarea.
 11. The device of claim 10 wherein the positive control area is inthe form of a symbol, and wherein further the symbol comprises a color.12. The device of claim 11, wherein the beads comprise a color that isdifferent from the color of the symbol of the positive control area. 13.The device of claim 9 wherein the analyte is selected from the groupconsisting of leutenizing hormone (LH), human chorionic gonadotropin(hCG), follicle stimulating hormone (FSH), hepatitis B surface antigen,human immunodeficiency virus (HIV), a bacteria-specific protein,creatinine, bilirubin, heavy metals, leukocytes, toxins, and a drug ofabuse.
 14. The device of claim 9 wherein the analyte is leutenizinghormone.
 15. The device of claim 9 wherein the positive control areacomprises two areas situated at either side of the analyte binding area.16. The device of claim 9 wherein the analyte is human chorionicgonadotropin.
 17. A method of determining the presence or absence of ananalyte in a liquid sample comprising: placing the liquid sample onto adevice comprising: a matrix that supports the flow of a liquid sample;an application zone on the matrix for receiving the liquid sample; oneor more reagent zones on the matrix comprising reagents for conductingthe assay; a detection zone on the matrix, the detection zone comprisingan analyte binding area and a positive control area demarcated on thematrix; wherein the analyte binding area and the positive control areainteract to form recognizable symbols indicative of the presence orabsence of analyte in the sample, and wherein at least a portion ofdetection zone is covered by an opaque, water-soluble dye; allowing theliquid sample to flow through the matrix and thereby pass through theone or more reagent zones so that reagents for conducting the assayreact with the liquid sample to form a detectable reaction product whenanalyte is present in the liquid sample; allowing the liquid sample toflow through the detection zone at least a portion of detection zone iscovered by an opaque, thereby washing away the opaque, water-soluble dyeto expose a positive control area; wherein analyte contained in thesample is restrained on the analyte binding area as sample flows throughthe detection zone; and observing the detection zone of the device forthe recognizable symbols indicative of the presence or absence ofanalyte in the liquid sample.
 18. The method of claim 17 wherein theanalyte is selected from the group consisting of leutenizing hormone(LH), human chorionic gonadotropin (hCG), follicle stimulating hormone(FSH), hepatitis B surface antigen, human immunodeficiency virus (HIV),a bacteria-specific protein, creatinine, bilirubin, heavy metals,leukocytes, toxins, and a drug of abuse.
 19. The method of claim 17wherein the analyte is leutenizing hormone.
 20. The method of claim 17wherein the matrix is a test strip comprised of a bibulous material; thepositive control area is comprised in the shape of a minus sign situatedlongitudinally along the axis of the bibulous material; and the analytebinding area comprises two areas situated on either side of the positivecontrol area.
 21. The method of claim 17 wherein the analyte is humanchorionic gonadotropin.
 22. A kit comprising: a device for performing anassay to detect the presence or absence of an analyte in a samplecomprising: a matrix that supports the flow of a liquid sample; anapplication zone on the matrix for receiving the liquid sample; one ormore reagent zones on the matrix comprising reagents for conducting theassay; a detection zone on the matrix, the detection zone comprising ananalyte binding area and a positive control area demarcated on thematrix; wherein the analyte binding area and the positive control areainteract to form recognizable symbols indicative of the presence orabsence of analyte in the sample, and wherein at least a portion ofdetection zone is covered by an opaque, water-soluble dye; andinstructions for use of the device.
 23. The kit of claim 22 wherein theanalyte binding area comprises two areas situated on either side of thepositive control area having a specific binding molecule for the analyteor for a molecule bound to the analyte, and the positive control areaand analyte binding area interact to form a recognizable symbol whenanalyte is present in the sample.
 24. The kit of claim 22 wherein theanalyte is selected from the group consisting of leutenizing hormone(LH), human chorionic gonadotropin (hCG), follicle stimulating hormone(FSH), hepatitis B surface antigen, human immunodeficiency virus (HIV),a bacteria-specific protein, creatinine, bilirubin, heavy metals,leukocytes, toxins, and a drug of abuse.
 25. The kit of claim 22 whereinthe analyte is selected from the group consisting of: human chorionicgonadotropin and leutenizing hormone.